TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33846845

Group type: EXPERIMENTAL
Intervention: PSMA PET
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: mpMR
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PET/MR
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 55
Study: 33846850

Group type: EXPERIMENTAL
Intervention: Stapedotomy
Number of subjects: 25
Study: 33847032

Group type: EXPERIMENTAL
Intervention: Support from parents and 'other important people' (e.g., friends, spouses)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Support from siblings with SCD
Number of subjects: 49
Study: 33847257

Group type: EXPERIMENTAL
Intervention: Low serum retinol (LSR) defined as serum retinol ≤20 µg/dl
Number of subjects: 803

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 803
Study: 33847298

Group type: EXPERIMENTAL
Intervention: Postvaccine period (2015-2016)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Prevaccine period (2007-2008)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: G2P[8], G1P[8], G4P[4], G9P[8], and G8P[8]
Number of subjects: 479
Study: 33847526

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33847588

Group type: EXPERIMENTAL
Intervention: Tech support plus health coaching intervention group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tech support intervention group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study: 33847874

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 9
Study: 33848093

Group type: EXPERIMENTAL
Intervention: Pediatric heat illness treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescent athletes undergoing high-intensity training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children trapped in closed spaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extreme temperatures and radiant heat exposure
Number of subjects: 0
Study: 33848199

Group type: EXPERIMENTAL
Intervention: Treatment-related changes in left atrial structure, specific details not available.
Number of subjects: 0
Study: 33848258

Group type: EXPERIMENTAL
Intervention: Surgical therapy, balloon pulmonary angioplasty, and medical therapy (details collected at enrollment and follow-up)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Quality of life surveys administered at enrollment and biannually
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Health care utilization data collected at follow-up
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Survival data collected throughout the study
Number of subjects: 750
Study: 33848277

Group type: EXPERIMENTAL
Intervention: Ultrasound attenuation parameter (UAP)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: FibroTouch examination
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: FibroTouch UAP
Number of subjects: 237
Study: 33849042

Group type: EXPERIMENTAL
Intervention: Flying intervention team model
Number of subjects: 2000000

Group type: COMPARATOR
Intervention: Mothership model
Number of subjects: 2000000

Group type: COMPARATOR
Intervention: Drip-and-ship model
Number of subjects: 2000000
Study: 33849298

Group type: EXPERIMENTAL
Intervention: Navitoclax plus docetaxel
Number of subjects: 0
Study: 33849466

Group type: EXPERIMENTAL
Intervention: Trifocal diffractive intraocular lens (IOL)
Number of subjects: 36
Study: 33849560

Group type: EXPERIMENTAL
Intervention: Postoperative computed tomography angiography (CT-angiography)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Registry data
Number of subjects: 94
Study: 33849562

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) for 5 weeks
Number of subjects: 15
Study: 33849625

Group type: EXPERIMENTAL
Intervention: No treatment limitations
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Treatment limitations
Number of subjects: 2186

Group type: COMPARATOR
Intervention: Patients without treatment limitations
Number of subjects: 2186

Group type: COMPARATOR
Intervention: Patients that died post ICU discharge
Number of subjects: 2186

Group type: COMPARATOR
Intervention: Patients with treatment limitations
Number of subjects: 2186
Study: 33849855

Group type: EXPERIMENTAL
Intervention: MyPal digital health platform (ePRO-based functionalities via mobile applications)
Number of subjects: 100
Study: 33849937

Group type: EXPERIMENTAL
Intervention: Mail order pharmacy use during shelter-in-place policy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33850048

Group type: EXPERIMENTAL
Intervention: Holistic ultrasound approach for extubation failure
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Diaphragm thickening fraction with cutoff value of < 30%
Number of subjects: 83
Study: 33851120

Group type: EXPERIMENTAL
Intervention: Arteriovenous Graft (AVG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Arteriovenous Fistula (AVF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 36
Study: 33851199

Group type: EXPERIMENTAL
Intervention: Food receipt paradigm
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Food picture paradigm
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Monetary reward paradigm
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Thin female model picture paradigm
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Visual processing regions in Studies 3 and 4
Number of subjects: 270
Study: 33851388

Group type: EXPERIMENTAL
Intervention: FXIII activity <70%
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Surgical patients and ICU patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Low FXIII activity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Hemostatic level of FXIII
Number of subjects: 97
Study: 33851429

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (cabergoline, quinagolide, bromocriptine)
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Dopamine agonists
Number of subjects: 3171

Group type: EXPERIMENTAL
Intervention: Dopamine agonists plus co-intervention (hydroxyethyl starch, human albumin, or coasting)
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Dopamine agonists plus co-intervention
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Cabergoline
Number of subjects: 3171
Study: 33851477

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg p.o. b.i.d. for 14 days followed by imiquimod 5% cream topically to the most clinically active lesions 3 days a week for 28 days
Number of subjects: 2
Study: 33852104

Group type: EXPERIMENTAL
Intervention: LY3022855 100 mg QW with durvalumab 750 mg Q2W
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LY3022855 50 or 100 mg QW with tremelimumab 75/225/750 mg Q4W
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: LY3022855 25/50/75/100 mg QW with durvalumab 750 mg Q2W
Number of subjects: 72
Study: 33852135

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: SU012662
Number of subjects: 65
Study: 33852146

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) treatment
Number of subjects: 18
Study: 33852450

Group type: EXPERIMENTAL
Intervention: Immunoglobulin A anti-tissue transglutaminase at the assay referenced upper limit of normal (30CU)
Number of subjects: 2353

Group type: COMPARATOR
Intervention: Thresholds extrapolated from the general population for the diagnostic evaluation of celiac disease
Number of subjects: 2353
Study: 33852969

Group type: EXPERIMENTAL
Intervention: Electrical uterine myography
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tocodynamometry
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intrauterine catheter
Number of subjects: 110
Study: 33853139

Group type: EXPERIMENTAL
Intervention: LATERA implant alone
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: LATERA implant + ITR
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: LATERA implant + septoplasty + ITR
Number of subjects: 277
Study: 33853394

Group type: EXPERIMENTAL
Intervention: Caregivers reporting anxiety symptoms
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Caregivers during COVID-19
Number of subjects: 34
Study: 33853608

Group type: EXPERIMENTAL
Intervention: Off-the-shelf active video games
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Self-paced custom active video games
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Custom active video games
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard of care stepping activities
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Game-paced custom active video games
Number of subjects: 15
Study: 33853614

Group type: EXPERIMENTAL
Intervention: SUPER intervention (combining robotics, virtual reality activities, and neuromuscular electrical stimulation)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Robotic-rehabilitation intervention focusing on elbow and shoulder movements (shoulder group; n=18)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EMG-triggered NMES in addition to robot therapy (hand group; n=10)
Number of subjects: 28
Study: 33854019

Group type: EXPERIMENTAL
Intervention: Extracorporeal Carbon Dioxide Removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extracorporeal Membrane Oxygenation
Number of subjects: 0
Study: 33854317

Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-6 mg/d)
Number of subjects: 2048
Study: 33854439

Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in supine with knee flexion of 60° (SUP60)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in seated with knee flexion of 60° (SIT60)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in supine with knee flexion of 20° (SUP20)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximum Electrically Induced Contraction (MEIC) in seated with knee flexion of 20° (SIT20)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Current efficiency (MEIC/maximum tolerated current amplitude)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonography of the quadriceps femoris (QF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tendon-aponeurosis complex (TAC) displacement
Number of subjects: 20
Study: 33854484

Group type: COMPARATOR
Intervention: Semaglutide (once-weekly subcutaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semaglutide (once-daily orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral semaglutide
Number of subjects: 0
Study: 33854566

Group type: EXPERIMENTAL
Intervention: FOLFIRI/bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI/aflibercept
Number of subjects: 0
Study: 33854572

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks to week 96
Number of subjects: 115
Study: 33854746

Group type: EXPERIMENTAL
Intervention: Modern therapeutic approaches for CTEPH (specific interventions not detailed in the abstract)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Combination of two or three methods in treatment of CTEPH (specific methods not detailed in the abstract)
Number of subjects: 516
Study: 33855205

Group type: EXPERIMENTAL
Intervention: Single autoantibody (n = 30)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Multiple autoantibodies (n = 46)
Number of subjects: 76
Study: 33855675

Group type: EXPERIMENTAL
Intervention: Mutant p.C182* IKAROS protein
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Follow-up observations
Number of subjects: 1
Study: 33855751

Group type: EXPERIMENTAL
Intervention: Exosomes carrying siRNA targeting STAT3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exosomes carrying antisense oligonucleotide (ASO) targeting STAT3
Number of subjects: 0
Study: 33855885

Group type: EXPERIMENTAL
Intervention: Modified CGM Algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limited field launch of Modified CGM Algorithm
Number of subjects: 0
Study: 33855888

Group type: EXPERIMENTAL
Intervention: Real-Time Continuous Glucose Monitoring
Number of subjects: 0
Study: 33856003

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (high-dose repletion therapy) for eight weeks
Number of subjects: 11
Study: 33856137

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (DW MRI)
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Combined mammography and ultrasound (US)
Number of subjects: 1148
Study: 33856277

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg and escalating doses of lenalidomide on Days 1-7 with DA-EPOCH-R (Days 1-5) in 21-day cycles
Number of subjects: 0
Study: 33856360

Group type: EXPERIMENTAL
Intervention: Adapted mobile NAS caregiving tool
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 33856599

Group type: EXPERIMENTAL
Intervention: PEG-BCT-100 at 2.7 mg/kg weekly intravenous
Number of subjects: 27
Study: 33857185

Group type: EXPERIMENTAL
Intervention: Inhaled sedation using volatile agents (Sevoflurane and Isoflurane) with the Anaesthetic Conserving Device (AnaConDa, Sedana Medical)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Inhaled sedation
Number of subjects: 187
Study: 33857326

Group type: EXPERIMENTAL
Intervention: Thrombolytics plus heparin
Number of subjects: 2401
Study: 33857451

Group type: EXPERIMENTAL
Intervention: 5 methylated DNA marker (MDM) panel
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 3 methylated DNA marker (MDM) panel
Number of subjects: 199
Study: 33857475

Group type: EXPERIMENTAL
Intervention: Hospital-acquired infections (HAIs)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Bloodstream infections (BSIs)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Catheter-related BSIs
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: HAIs complicated by septic shock
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation duration
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: ICU stay duration
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Hospital stay duration
Number of subjects: 774
Study: 33857524

Group type: EXPERIMENTAL
Intervention: Generalized fractional anisotropy (GFA) values of white matter (WM) tracts in children with ADHD
Number of subjects: 77

Group type: COMPARATOR
Intervention: Generalized fractional anisotropy (GFA) values of white matter (WM) tracts in typically developing controls (TDC)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ADHD symptom severity and diagnosis
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Full-scale intellectual quotient (FIQ)
Number of subjects: 77
Study: 33857679

Group type: EXPERIMENTAL
Intervention: Two doses of 9vHPV vaccine (day 1 and month 12, 24, 36, or 60) in Cohorts 1-4
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: One study dose of 9vHPV vaccine at day 1 in Cohort 0
Number of subjects: 700

Group type: COMPARATOR
Intervention: Three doses of 9vHPV vaccine (day 1, months 2 and 6) in Cohort 5
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Injection-site and systemic adverse events (AEs)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Serious adverse events (AEs)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Vaccine-related serious AEs and deaths
Number of subjects: 700
Study: 33857731

Group type: EXPERIMENTAL
Intervention: DREAMIES (frequency-selective hearing protection device) worn for two consecutive 30-min periods in Phase 1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DREAMIES worn between care and feeding times during an 8-h Device-On period followed by an 8-h Device-Off period for three consecutive days in Phase 2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nurse evaluation of DREAMIES
Number of subjects: 50
Study: 33857917

Group type: EXPERIMENTAL
Intervention: e-CBT
Number of subjects: 146

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Combination of e-CBT and medication
Number of subjects: 146
Study: 33858040

Group type: EXPERIMENTAL
Intervention: Dasatinib combined with multi-agent chemotherapy regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33858202

Group type: EXPERIMENTAL
Intervention: Chemotherapy (adjuvant or neoadjuvant)
Number of subjects: 0
Study: 33858278

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 33858326

Group type: EXPERIMENTAL
Intervention: SDC2 methylation test using EarlyTect™-Colon Cancer test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33858336

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 0
Study: 33858486

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges (2/day for 90 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTZ (400 mg) and AMX (500 mg TID for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic lozenges and MTZ+AMX
Number of subjects: 0
Study: 33858803

Group type: EXPERIMENTAL
Intervention: Rurality (caregivers from rural areas)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Rurality among caregivers with education ≤ high school
Number of subjects: 414
Study: 33859147

Group type: EXPERIMENTAL
Intervention: Expedited partner treatment (EPT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Partner HIV self-testing (HIVST)
Number of subjects: 63
Study: 33859572

Group type: EXPERIMENTAL
Intervention: Short-term resistance-training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 33859620

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 33
Study: 33859707

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group, transcutaneous EA on Bai-hui (GV20), Nei-guan (PC6), Tian-shu (ST25), and Zu-san-li (ST36) once a day in the afternoon.
Number of subjects: 385

Group type: COMPARATOR
Intervention: Sham EA (control group).
Number of subjects: 385
Study: 33859944

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygenation plus Hypofractionated Stereotactic Radiotherapy (HBO-RT)
Number of subjects: 9
Study: 33860280

Group type: EXPERIMENTAL
Intervention: Intra-operative infusion of [U-13C] glucose
Number of subjects: 22
Study: 33860387

Group type: EXPERIMENTAL
Intervention: Prosigna test
Number of subjects: 809

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 809
Study: 33860406

Group type: EXPERIMENTAL
Intervention: Impaired intraoperative cerebrovascular autoregulation (CVA)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Radical prostatectomy
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Premedication with midazolam
Number of subjects: 195
Study: 33860531

Group type: EXPERIMENTAL
Intervention: Antidepressants (specifically Venlafaxine)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 626

Group type: COMPARATOR
Intervention: NRSIs
Number of subjects: 626
Study: 33860864

Group type: EXPERIMENTAL
Intervention: Capacitive radiofrequency (BTL-6000 TR-Therapy Pro®) applied for 10 min with epidermal temperature above 40°C
Number of subjects: 5
Study: 33860922

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole treatment for 8 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole treatment
Number of subjects: 96
Study: 33860951

Group type: EXPERIMENTAL
Intervention: 12-month abstinent
Number of subjects: 4030

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorder (AUD)
Number of subjects: 4030

Group type: COMPARATOR
Intervention: Low-risk drinkers
Number of subjects: 4030
Study: 33861204

Group type: EXPERIMENTAL
Intervention: Movn mobile app, supportive push-through messages (3 times per week), and Charge 2 (Fitbit Inc) activity tracker
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care with pedometer and daily steps recorded in a diary
Number of subjects: 60
Study: 33861209

Group type: EXPERIMENTAL
Intervention: Electronic health record-embedded individualized pain plans
Number of subjects: 160
Study: 33861210

Group type: EXPERIMENTAL
Intervention: SPARC intervention (Sex Workers Promoting Action, Risk Reduction, and Community Mobilization) drop-in center and mobile outreach program; services include harm reduction, reproductive health, sexual health care, medication-assisted treatment, legal aid, counseling, and distribution of harm reduction tools.
Number of subjects: 385

Group type: COMPARATOR
Intervention: Control group (participants from areas of Baltimore not predefined as closest to SPARC).
Number of subjects: 385
Study: 33861212

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol and stigma coping
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control topics only
Number of subjects: 500
Study: 33861303

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 167
Study: 33861486

Group type: EXPERIMENTAL
Intervention: Trametinib 2.0 mg daily
Number of subjects: 9
Study: 33861558

Group type: EXPERIMENTAL
Intervention: Functional Status Scale score
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Quadriceps muscle size
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mobility function scores
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Physical health-related quality of life
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Child physical health-related quality of life at hospital discharge
Number of subjects: 73
Study: 33862302

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unchanged regimens (Control)
Number of subjects: 10
Study: 33863399

Group type: EXPERIMENTAL
Intervention: Custom virtual reality simulator training for ophthalmologic surgical procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custom virtual reality simulator training for PDS implantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custom virtual reality simulator training
Number of subjects: 0